GELS
GELS
NASDAQ · Pharmaceuticals

Gelteq Ltd

$0.57
0.00 (-0.52%)
As of Aug 8, 2:32 AM ET ·
Financial Highlights (FY 2026)
Revenue
189.5K
Net Income
-7,581,278
Gross Margin
30.3%
Profit Margin
-4,011.7%
Rev Growth
+3.9%
D/E Ratio
0.27
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 30.3% 30.3% 30.0% 30.0%
Operating Margin -3,015.9% -2,714.3% 23.0% 18.9%
Profit Margin -4,011.7% -3,811.2% 17.2% 17.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 189.5K 182.3K 1.91M 1.66M
Gross Profit 57.5K 55.3K 574.2K 499.6K
Operating Income -5,715,357 -4,949,313 441.1K 315.2K
Net Income -7,581,278 -6,565,140 328.9K 295.4K
Gross Margin 30.3% 30.3% 30.0% 30.0%
Operating Margin -3,015.9% -2,714.3% 23.0% 18.9%
Profit Margin -4,011.7% -3,811.2% 17.2% 17.7%
Rev Growth +3.9% +3.9% -9.8% +4.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 647.4K 647.4K 1.31M 1.18M
Total Equity 2.43M 2.43M 6.78M 6.33M
D/E Ratio 0.27 0.27 0.19 0.19
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -4,304,779 -3,934,898 495.2K 517.1K
Free Cash Flow 411.8K 446.0K